CI
CINGW
Cingulate Inc.
$0.0181
-69.88%
$323.3K
No data for this timeframe.
Vol
Market Cap$323.3K
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$157.00
SEC Reports5
Press Releases1
Recent Activity
Jun 2, 2026
SEC
Cingulate received a Complete Response Letter (CRL) from the FDA for its lead NDA, CTx-1301 (ADHD), citing only Chemistr
8-K — Impact 7/10
May 19, 2026
SEC
Cingulate reported that Class II directors Jeff Ervin and Jay Roberts will not stand for re-election at the 2026 Annual
8-K — Impact 2/10
May 14, 2026
SEC
Cingulate Inc. reported Q1 2026 results with a net loss of $9.3M, widening from a $3.9M loss in Q1 2025, driven by a 287
8-K — Impact 5/10
May 14, 2026
earnings
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cash Position Grows to $25.9 Million <pre>Cash Position Grows to $25.9 Million</pre>
Mar 18, 2026
Press
Cingulate Inc. reported its Q4 and full-year 2025 financial results, highlighted by a $12 million PIPE financing, U.S. a
Impact 6/10
Latest Reports
BEARISH
8-K
7/10
Cingulate received a Complete Response Letter (CRL) from the FDA for its lead NDA, CTx-1301 (ADHD), citing only Chemistr
Jun 2, 2026
NEUTRAL
8-K
2/10
Cingulate reported that Class II directors Jeff Ervin and Jay Roberts will not stand for re-election at the 2026 Annual
May 19, 2026
MIXED
Press
6/10
Cingulate Inc. reported its Q4 and full-year 2025 financial results, highlighted by a $12 million PIPE financing, U.S. a
Mar 18, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $157.00 | — |
1 institutional holders with $157.00 total value (2,900 shares) as of 2025-Q3. Top holders: UBS.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 2,900 | $157.00 | 100.0% | — |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 5.0/10.
BEARISH
8-K
7/10
Cingulate received a Complete Response Letter (CRL) from the FDA for its lead NDA, CTx-1301 (ADHD),
Jun 2, 2026
NEUTRAL
8-K
2/10
Cingulate reported that Class II directors Jeff Ervin and Jay Roberts will not stand for re-election
May 19, 2026
NEUTRAL
8-K
5/10
Cingulate Inc. reported Q1 2026 results with a net loss of $9.3M, widening from a $3.9M loss in Q1 2
May 14, 2026
NEUTRAL
PRESS-RELEASE
5/10
Cingulate reported a net loss of $9.3M for Q1 2026, widening from $3.9M a year ago, driven by a surg
May 14, 2026
BEARISH
EFFECT
6/10
Cingulate Inc.'s S-3 shelf registration has become effective, allowing the company and selling stock
Apr 27, 2026
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 647.6% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
earnings
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cash Position Grows to $25.9 Million <pre>Cash Position Grows to $25.9 Million</pre>
Mar 18, 2026
earnings
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market Pricing